Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to get Screeners that run automatically with the results emailed to you! FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Oncolytics Biotech Inc (ONCY)

Oncolytics Biotech Inc (ONCY)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 64,048
  • Shares Outstanding, K 77,074
  • Annual Sales, $ 0 K
  • Annual Income, $ -20,560 K
  • EBIT $ -26 M
  • EBITDA $ -26 M
  • 60-Month Beta 1.63
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 10.30
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -0.27
  • Most Recent Earnings $-0.09 on 11/12/24
  • Next Earnings Date N/A
  • Annual Dividend & Yield N/A (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 7 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/24
See More
  • Average Estimate -0.08
  • Number of Estimates 2
  • High Estimate -0.07
  • Low Estimate -0.09
  • Prior Year -0.04
  • Growth Rate Est. (year over year) -100.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.7101 +17.03%
on 12/19/24
0.9999 -16.89%
on 11/22/24
-0.1675 (-16.78%)
since 11/20/24
3-Month
0.7101 +17.03%
on 12/19/24
1.5300 -45.69%
on 10/07/24
-0.0929 (-10.06%)
since 09/20/24
52-Week
0.7101 +17.03%
on 12/19/24
1.5300 -45.69%
on 10/07/24
-0.4090 (-32.98%)
since 12/20/23

Most Recent Stories

More News
Oncology Advancements Accelerate Amid Rising Early-Onset Cancer Diagnoses

EQNX::TICKER_START (NASDAQ:ONCY),(TSX:ONC),(NASDAQ:CRDF),(NASDAQ:PSNL),(NASDAQ:TEM),(NASDAQ:CKPT) EQNX::TICKER_END

ONCY : 0.8310 (-6.36%)
CKPT : 3.75 (+11.28%)
PSNL : 5.75 (+9.32%)
ONC.TO : 1.19 (-9.16%)
TEM : 35.54 (+7.60%)
CRDF : 4.26 (-5.12%)
Oncology Advancements Accelerate Amid Rising Early-Onset Cancer Diagnoses

/CNW/ -- USA News Group News Commentary – The American Cancer Society has published its Advances in Oncology – 2024 Research Highlights, underscoring major...

ONCY : 0.8310 (-6.36%)
CKPT : 3.75 (+11.28%)
PSNL : 5.75 (+9.32%)
ONC.TO : 1.19 (-9.16%)
TEM : 35.54 (+7.60%)
CRDF : 4.26 (-5.12%)
From Crisis to Opportunity: How Advances in Immunotherapy Are Shaping the Oncology Sector

Issued on behalf of Oncolytics Biotech Inc. VANCOUVER – USA News Group News Commentary – Despite significant advances in oncology research, challenges remain as the American Cancer Society...

ONCY : 0.8310 (-6.36%)
PYXS : 1.6900 (+9.74%)
RPTX : 1.3200 (unch)
IMRX : 2.00 (+8.70%)
CVM : 0.7299 (-4.60%)
ONC.TO : 1.19 (-9.16%)
Cancer Care Disruptions Highlight Growing Demand for Innovative Oncology Treatments

/CNW/ -- USA News Group News Commentary – The American Cancer Society recently released its Advances in Oncology – 2024 Research Highlights report that...

ONCY : 0.8310 (-6.36%)
CKPT : 3.75 (+11.28%)
LLY : 767.76 (+1.35%)
ONC.TO : 1.19 (-9.16%)
OSTX : 3.97 (+1.53%)
CRDF : 4.26 (-5.12%)
Early-Onset Cancer Trends Spark Interest in Promising Oncology Pipelines

Issued on behalf of Oncolytics Biotech Inc. VANCOUVER – USA News Group News Commentary – The American Cancer Society has unveiled its Advances in Oncology – 2024 Research Highlights report,...

ONCY : 0.8310 (-6.36%)
PSNL : 5.75 (+9.32%)
ALXO : 1.6200 (+9.46%)
ONC.TO : 1.19 (-9.16%)
NVCT : 4.52 (-3.62%)
TEM : 35.54 (+7.60%)
Promising Data for Treating Gastrointestinal Cancer Leading to Hopeful Advancements for Pancreatic & Anal Cancers

EQNX::TICKER_START (NASDAQ:ONCY),(TSX:ONC),(NYSE:NVS),(NYSE:PFE),(NYSE:GSK),(NYSE:BMY) EQNX::TICKER_END

ONCY : 0.8310 (-6.36%)
NVS : 97.11 (+0.35%)
ONC.TO : 1.19 (-9.16%)
PFE : 26.36 (+2.29%)
GSK : 33.60 (+0.51%)
BMY : 57.33 (+1.83%)
Oncolytics Biotech® to Present Promising Pelareorep Data in Pancreatic and Anal Cancers at ASCO GI Symposium

SAN DIEGO, CA and CALGARY, AB – December 18, 2024 – Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), a leading clinical-stage company specializing in immunotherapy for oncology, today announced...

ONCY : 0.8310 (-6.36%)
ONC.TO : 1.19 (-9.16%)
Oncolytics Biotech® to Present Promising Pelareorep Data in Pancreatic and Anal Cancers at ASCO GI Symposium

/CNW/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), a leading clinical-stage company specializing in immunotherapy for oncology, today announced the...

ONCY : 0.8310 (-6.36%)
ONC.TO : 1.19 (-9.16%)
Oncolytics Biotech® Reports Completion of Initial Safety Phase Enrollment for GOBLET Trial's New Pancreatic Cancer Cohort

/CNW/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), a leading clinical-stage company specializing in immunotherapy for oncology, today announced that...

ONCY : 0.8310 (-6.36%)
ONC.TO : 1.19 (-9.16%)
Biotech Advances Drive Cancer Research as Global Rates Continue Upward Trend

/CNW/ -- USA News Group News Commentary – Despite death rates for some cancers being on the decline, there is a global surge in cancer cases among people under...

ONCY : 0.8310 (-6.36%)
CKPT : 3.75 (+11.28%)
RCUS : 15.50 (+0.26%)
BCTX : 0.5610 (-4.12%)
ONC.TO : 1.19 (-9.16%)
AKYA : 2.49 (-2.35%)

Business Summary

Oncolytics Biotech, Inc. focuses on the discovery and development of pharmaceutical products for the treatment of a wide variety of human and companion pet cancers. The Company was formed to explore the oncolytic capability of the reovirus, a virus that preferentially replicates in cells with an activated...

See More

Key Turning Points

3rd Resistance Point 1.0007
2nd Resistance Point 0.9503
1st Resistance Point 0.8907
Last Price 0.8310
1st Support Level 0.7807
2nd Support Level 0.7303
3rd Support Level 0.6707

See More

52-Week High 1.5300
Fibonacci 61.8% 1.2168
Fibonacci 50% 1.1200
Fibonacci 38.2% 1.0233
Last Price 0.8310
52-Week Low 0.7101

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar